These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 37197442)

  • 21. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Yu Y; Zheng P; Gao L; Li H; Tao P; Wang D; Ding F; Shi Q; Chen H
    J Immunother; 2021 Feb-Mar 01; 44(2):76-85. PubMed ID: 33208635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study.
    Guven DC; Acar R; Yekeduz E; Bilgetekin I; Baytemur NK; Erol C; Ceylan F; Sendur MA; Demirci U; Urun Y; Karadurmus N; Erman M; Kilickap S
    Curr Probl Cancer; 2021 Dec; 45(6):100760. PubMed ID: 34130864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC.
    Metselaar-Albers M; Meijerman I; Engels F; Haanen J; Beijnen J; Lalmohamed A
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
    Li X; Ding X; Li W; Chen J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis.
    Yang M; Wang Y; Yuan M; Tao M; Kong C; Li H; Tong J; Zhu H; Yan X
    Int Immunopharmacol; 2020 Nov; 88():106876. PubMed ID: 32799113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients.
    Huang XZ; Gao P; Song YX; Xu Y; Sun JX; Chen XW; Zhao JH; Wang ZN
    Oncoimmunology; 2019; 8(12):e1665973. PubMed ID: 31741763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.
    Fulgenzi CAM; Scheiner B; D'Alessio A; Mehan A; Manfredi GF; Celsa C; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Pinter M; Sharma R; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Napolitano A; Vivaldi C; Salani F; Masi G; Silletta M; Lo Prinzi F; Di Giacomo E; Vincenzi B; Bettinger D; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Pirisi M; Park JW; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Ghittoni G; Cammà C; Stefanini B; Trevisani F; Giannini EG; Cortellini A; Pinato DJ
    JAMA Oncol; 2024 Sep; 10(9):1253-1258. PubMed ID: 39023864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
    Celsa C; Cabibbo G; Fulgenzi CAM; Scheiner B; D'Alessio A; Manfredi GF; Nishida N; Ang C; Marron TU; Saeed A; Wietharn B; Pinter M; Cheon J; Huang YH; Lee PC; Phen S; Gampa A; Pillai A; Vivaldi C; Salani F; Masi G; Roehlen N; Thimme R; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; El Tomb P; Ulahannan S; Parisi A; Chon HJ; Hsu WF; Stefanini B; Verzoni E; Giusti R; Veccia A; Catino A; Aprile G; Guglielmini PF; Di Napoli M; Ermacora P; Antonuzzo L; Rossi E; Verderame F; Zustovich F; Ficorella C; Di Pietro FR; Battelli N; Negrini G; Grossi F; Bordonaro R; Pipitone S; Banzi M; Ricciardi S; Laera L; Russo A; De Giorgi U; Cavanna L; Sorarù M; Montesarchio V; Bordi P; Brunetti L; Pinto C; Bersanelli M; Cammà C; Cortellini A; Pinato DJ
    J Hepatol; 2024 Mar; 80(3):431-442. PubMed ID: 37972660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
    Jin ZC; Chen JJ; Zhu XL; Duan XH; Xin YJ; Zhong BY; Chen JZ; Tie J; Zhu KS; Zhang L; Huang M; Piao MJ; Li X; Shi HB; Liu RB; Xu AB; Ji F; Wu JB; Shao GL; Li HL; Huang MS; Peng ZY; Ji JS; Yuan CW; Liu XF; Hu ZC; Yang WZ; Yin GW; Huang JH; Ge NJ; Qi X; Zhao Y; Zhou JW; Xu GH; Tu Q; Lin HL; Zhang YJ; Jiang H; Shao HB; Su YJ; Chen TS; Shi BQ; Zhou X; Zhao HT; Zhu HD; Ren ZG; Teng GJ;
    EClinicalMedicine; 2024 Jun; 72():102622. PubMed ID: 38745965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
    Hsu WF; Wang HW; Chen CK; Lai HC; Chuang PH; Tsai MH; Su WP; Chen HY; Chu CS; Chou JW; Chen SH; Tsai TY; Hsiao WD; Lin CC; Huang GT; Lin JT; Peng CY
    Am J Cancer Res; 2021; 11(12):6173-6187. PubMed ID: 35018250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.
    Luo Z; Hao S; Li Y; Cheng L; Zhou X; Gunes EG; Liu S; Chen J
    Front Immunol; 2022; 13():1065004. PubMed ID: 36505435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
    Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
    Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.
    Castello A; Rossi S; Toschi L; Lopci E
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis.
    Qian X; Guo X; Li T; Hu W; Zhang L; Wu C; Ye F
    Front Pharmacol; 2022; 13():926890. PubMed ID: 36071838
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.